asx:rad

Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at…
Read More...

"This is the first approval for TEPEZZA in Asia and marks a significant milestone for the global treatment of…
Read More...

Key results include: For the second quarter, total revenues increased 20% to $8.4 billion in comparison to the…
Read More...

At this year’s Collision event, held in Toronto from June 18 to 20, Wesley Chan, co-founder and managing partner at…
Read More...